Stryker (NYSE:SYK) Trading Down 7.5% After Analyst Downgrade

Stryker Corporation (NYSE:SYK) dropped 7.5% on Friday after BTIG Research lowered their price target on the stock from $371.00 to $358.00. BTIG Research currently has a buy rating on the stock. Stryker traded as low as $317.62 and last traded at $322.0220. Approximately 881,207 shares changed hands during trading, a decline of 62% from the average session volume of 2,349,355 shares. The stock had previously closed at $348.04.

SYK has been the subject of a number of other reports. Leerink Partners cut their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Argus set a $370.00 target price on Stryker in a report on Thursday, July 9th. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Evercore set a $350.00 price objective on shares of Stryker in a research report on Monday, July 6th. Finally, Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $392.40.

Insider Activity

In related news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is owned by insiders.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reported second-quarter adjusted EPS of $3.69, ahead of the $3.49 consensus estimate and up 17.9% year over year. Revenue rose 9.4% to $6.59 billion, broadly matching expectations, as demand remained strong for orthopedic, spinal and other medical devices. Reuters earnings article
• Positive Sentiment: Management reported 9% organic sales growth, a 66% adjusted gross margin and progress recovering from the March cyberattack. The company also resumed share repurchases, potentially supporting earnings and shareholder returns. MassDevice cyberattack recovery article
• Positive Sentiment: Stryker reaffirmed a strong 2026 outlook, forecasting 8.3%-9.3% organic sales growth and adjusted EPS of $14.95-$15.10. The midpoint is generally in line with Wall Street expectations, while the narrowed range signals improved visibility. Stryker 2026 outlook article
• Neutral Sentiment: UBS initiated research coverage on Stryker, adding another institutional view, although the initial rating and target were not provided in the available report. UBS coverage article
• Negative Sentiment: BTIG Research lowered its price target from $371 to $358, leaving only limited implied upside, although it maintained a Buy rating. The reduced target may weigh on sentiment, particularly with Stryker trading at roughly 40 times earnings. BTIG price target article
• Negative Sentiment: Despite the EPS beat, the stock declined after quarterly sales came in essentially in line with estimates. Investors may also remain concerned about lingering operational effects and costs from the cyberattack, as well as the premium valuation.

Institutional Investors Weigh In On Stryker

A number of institutional investors have recently modified their holdings of SYK. Godfrey Financial Associates Inc. bought a new position in Stryker during the fourth quarter worth about $26,000. Sankala Group LLC bought a new stake in Stryker in the 4th quarter valued at about $26,000. United Financial Planning Group LLC acquired a new position in shares of Stryker during the 3rd quarter worth approximately $27,000. Atlas Capital Advisors Inc. acquired a new position in shares of Stryker during the 4th quarter worth approximately $27,000. Finally, DJE Kapital AG bought a new position in shares of Stryker during the fourth quarter worth approximately $28,000. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 7.8%

The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The business’s 50-day moving average price is $317.08 and its two-hundred day moving average price is $334.98. The company has a market capitalization of $122.98 billion, a price-to-earnings ratio of 37.29, a P/E/G ratio of 2.26 and a beta of 0.77.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the prior year, the business posted $3.13 earnings per share. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts predict that Stryker Corporation will post 14.99 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio is 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.